ABSTRACT
In a comparative study of a total of 5740 unselected patients of both sexes, that had been admitted as inpatients for rehabilitation reasons concerning rheumatic diseases, it has been examined which differences result between 1976 and 1988 with respect to the prevalence of one or more of the following 5 diseases: diseases of the liver, arterial hypertension, disturbances of the lipid, uric acid or carbohydrate metabolism. Underlying were the same conditions and valuation standards. 2155 consecutively hospitalized patients in 1976 of a medium age of 53.75 +/- 10.89 years (standard deviation) were compared to 3585 patients with a medium age of 55.25 +/- 10.74 years in 1988. Age structure, professions and social levels were comparable in both populations. Whereas 1976 41.1% of the males and 27.9% of the females had one or more of the 5 diseases, this applied for 71.0% of the males and 59.5% of the females in 1988. Between 1976 and 1988 diseases of the liver, arterial hypertension, hyperlipoproteinemia and impairment of carbohydrate metabolism increased highly significant by 66%, 73%, 128% and 41%, respectively. Also hyperuricemia was found more frequently in 1988 among males than 1976 (17.9% vs. 14.2%), whereas among females the prevalence lowered significantly from 8.5% to 4.5% during this period. At the same time the prevalence of overweight of more than 20% of the ideal weight increased from 56.6% of the patients suffering from one or more of the 5 diseases in 1976 to 63.9% in 1988 significantly. Of a total of 3585 patients that was investigated in 1988 2395 patients (66.8%) had one or more of the additional diseases.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Cause of Death , Health Education/trends , Life Style , Mortality/trends , Cross-Sectional Studies , Germany , Humans , Risk FactorsSubject(s)
Circadian Rhythm , Hydroxymethylglutaryl CoA Reductases/physiology , Lipids/blood , Adult , Aged , Anticholesteremic Agents/pharmacology , Female , Humans , Male , Middle AgedABSTRACT
Patients with hyperlipoproteinemia, type IIa, were treated with an adequate diet; additionally they were given 500 mg etofibrate daily. Within 14 days the total cholesterol-level in serum, LDL and LDL-cholesterol were reduced significantly, whereas the level of HDL was not affected. The potency of etofibrate is equal to approximately 50 to 80% of the lipid-lowering effect of clofibrate in an optimal dosis of 2 g/day.
Subject(s)
Anticholesteremic Agents/administration & dosage , Clofibrate/analogs & derivatives , Clofibric Acid/analogs & derivatives , Hyperlipoproteinemia Type II/drug therapy , Adult , Aged , Anticholesteremic Agents/therapeutic use , Clofibric Acid/administration & dosage , Clofibric Acid/therapeutic use , Delayed-Action Preparations , Female , Humans , Male , Middle AgedABSTRACT
If patients with hyperlipoproteinemia type IIa are treated with diet and additionally over a period of two weeks with 2 grams of Clofibrate daily, the cholesterol-level in the serum decreases. This decrease is caused mainly by a reduction of the apolipoprotein B and the LDL-cholesterol in serum. If elevated cholesterol-levels in the serum are reduced through a "prudent" diet, the concentration of apolipoprotein B in serum remains the same. It is not fully understood which influence a diet, which is rich in poly-unsaturated fatty acids and has a low content of saturated fatty acids and carbohydrates, has upon the lipoproteins in the serum. The mode of action of this diet and its significance for the concentration of HDL need further investigation.
Subject(s)
Apolipoproteins/blood , Clofibrate/therapeutic use , Hypercholesterolemia/diet therapy , Hypercholesterolemia/drug therapy , Lipoproteins, LDL/blood , Aged , Female , Humans , Hypercholesterolemia/blood , Male , Middle AgedABSTRACT
After changing over from the usual eating habits to a "reasonable" restricted diet rich in polyene saturated fats and saturated fatty acids, additional treatment with 1 g clofibrate twice daily produces a significant reduction of concentration of total cholesterol and Apo B by about 24% in the serum of patients with Type IIa hyperlipoproteinemia after 2 weeks. In contrast to this the serum concentration of triglycerides and phospholipids shows an insignificant tendency to fall during the whole duration of the trial. The results suggest that the additional cholesterol reducing action of clofibrate in patients with hyperlipoproteinemia Type IIa who have already been treated by diet is mainly achieved by the reduction of LDL-cholesterol, the atherogenic properties of which are well known.